Targeting the dopamine D2 receptor in schizophrenia

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 4, 2006, Pages 515-531

  Seeman, Philip ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic; Brain imaging; Domperidone; Dopamine receptor; Psychosis; Schizophrenia; Supersensitivity

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMISULPRIDE; AMOXAPINE; AMPHETAMINE; ARIPIPRAZOLE; BUTACLAMOL; CHLORPROMAZINE; CLOZAPINE; CYPROHEPTADINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; EPIDEPRIDE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LOXAPINE; MELPERONE; MOLINDONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORCLOZAPINE; OLANZAPINE; PERPHENAZINE; PROLACTIN; TRITIUM; UNINDEXED DRUG;

BINDING SITE; BRAIN DAMAGE; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SENSITIZATION; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROTRANSMISSION; NOMENCLATURE; NONHUMAN; PARKINSONISM; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; METABOLISM;

ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 33746768115     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.4.515     Document Type: Review

References (92)

1. SIGWALD J, BOUTTIER D: 3-Chloro-10-(3′-dimethylaminopropyl)-phenothia-zine hydrochloride in current neuro-psychiatry. Ann. Méd. Interne (Paris) (1953) 54(2):150-182.
2. DELAY J, DENIKER P, HARL J-M.: Traitement des états d'excitation et d'agitation par une méthode médicamenteuse dérivée de l'hibernithérapie. [Therapeutic method derived from hiberno-therapy in excitation and agitation states.] Ann. Méd-Psychol. (Paris) (1952) 110:267-273.
3. AGID O, KAPUR S, ARENOVICH T, ZIPURSKY RB: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiat (2003) 60:1228-1235.
4. SEEMAN P: The membrane actions of anesthetics and tranquilizers. Pharmacol. Rev. (1972) 24:583-655.
5. SEEMAN P, BIALY HS: The surface activity of tranquilizers. Biochem. Pharmacol. (1963) 12:1181-1191.
6. EHRINGER H, HORNYKIEWICZ O: Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. (1960) 38:1236-1239.
7. ZINGALES IA: A gas chromatographic method for the determination of haloperidol in human plasma. J. Chromatogr. (1971) 54:15-24.
8. HEISS WD, HOYER J: Dopamine receptor blockade by neuroleptic drugs in Aplysia neurones. Experientia (1974) 30:1318-1320.
9. STRUYKER BOUDIER HAJ, GIELEN W, COOLS AR, VAN ROSSUM JM: Pharmacological analysis of dopamine-induced inhibition and excitation of neurones of the snail Helix Aspersa. Arch. Int. Pharmacodyn. Ther. (1974) 209:324-331.
10. CARLSSON A, LINDQVIST M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.) (1963) 20:140-144.
11. ANDÉN N-E, ROOS B-E, WERDINIUS B: Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum. Life Sci. (1964) 3:149-158.
12. ANDÉN N-E, BUTCHER SG, CORRODI H, FUXE K, UNGERSTEDT U: Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur. J. Pharmacol. (1970) 11:303-314.
13. KEBABIAN JW, GREENGARD P: Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science (1971) 174:1346-1349.
14. SEEMAN P: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (1987) 1:133-152.
15. SEEMAN P, CHAU-WONG M, TEDESCO J, WONG K: Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. USA (1975) 72:4376-4380.
16. SEEMAN P, LEE T, CHAU-WONG M, WONG K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (Lond) (1976) 261:717-719.
17. KEBABIAN JW, CALNE DB: Multiple receptors for dopamine. Nature (1979) 277:93-96.
18. 3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol. Pharmacol. (1976) 12:800-812.
19. 3H]haloperidol. Psychopharmacol. Commun. (1975) 1:663-673.
20. SEEMAN P: Brain dopamine receptors. Pharmacol. Rev. (1980) 32:229-313.
21. 3) as a target for neuroleptics. Nature (1990) 347:146-151.
22. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiat. (1992) 49:538-544
23. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia: clinical and theoretical implications. Am. J. Psychiatry (1999) 156:286-293.
24. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine. Am. J. Psychiatry (1999) 156:876-884.
25. 3 dopamine receptor occupancy by quetiapine in vivo. Br. J. Psychiat. (2000) 177:408-415.
26. 123I]epidepride SPET study of amisulpride-treated patients. Amer. J. Psychiat. (2003) 160:1413-1420.
27. 3 receptors by olanzapine and haloperidol. Neuropsychopharmacology (2005) 30:2283-2289.
28. TURRONE P, KAPUR S, SEEMAN MV, FLINT AJ: Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry (2002) 159:133-135.
29. MAURI MC, STEINHILBER CP, MARINO R et al.: Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry (2005) 20:55-60.
30. SEEMAN P: Atypical antipsychotics: mechanism of action. Can. J. Psychiatry (2002) 47:27-38.
31. KASSAHUN K, MATTIUZ E, NYHART JR E et al.: Disposition and biotrans-formation of the antipsychotic agent olanzapine in humans. Drug Metabol. Disposit. (1997) 25:81-93.
32. 4. Neuropsychopharmacology (1992) 7:261-284.
33. SCHABER G, STEVENS I, GAERTNER HJ, DIETZ K, BREYER-PFAFF U: Pharmakokinetics of clozapine and its metabolites in psychiatric patient: plasma protein binding and renal clearance. Br. J. Clin. Pharmacol. (1998) 46:453-459.
34. PERRY PJ, LUND BC, SANGER T, BEASLEY C: Olanzapine plasma concentrations and clinical response: Acute phase results of the North American olanzapine trial. J. Clin. Pscychopharmacol. (2001) 21:14-20.
35. AICHORN W, MARSTEINER J, WALCH T, ZERNIG G, SARIA A, KEMMLER G: Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int. Clin. Psychopharmacol. (2006) 21:81-85.
36. MCCONVILLE BJ, ARVANITIS LA, THYRUM PT et al.: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J. Clin. Psychiat. (2000) 61:252-260.
37. MALLIKAARJUN S, SALAZAR DE, BRAMER SL: Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J. Clin. Pharmacol. (2004) 44:1179-1187.
38. LIN S-K, CHANG W-H, CHUNG M-C, LAM YWF, JANN MW: Disposition of clozapine and demethylclozapine in schizophrenic patients. J. Clin. Pharmacol. (1994) 34:318-324.
39. LIEBERMAN J, JOHNS C, POLLACK S et al.: Biochemical effects of cloza-pine in cerebrospinal fluid of patients with schizophrenia. In: Advances in Neuropsychiatry and Psychopharmacology volume I: Schizophrenia Research, CA Taminga and SC Schulz (Eds), Raven Press, New York, USA (1991):341-349.
40. NORDIN C, ALMÉ B, BONDESSON U: CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study. Psychopharmacology (1995) 122:104-107.
41. HASEGAWA M, GUTERREZ-ESTEINOU R, WAY L, MELTZER HY: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J. Clin. Psychopharmacol. (1993) 13:383-390.
42. OLESEN OV, THOMSEN K, JENSEN PN et al.: Clozapine serum levels and side effects during steady state treatment of schiophrenic patients; a cross-sectional study. Psychopharmacology (1995) 117:371-378.
43. PERRY PJ, MILLER DD, ARNDT SV, CADORET RJ: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiat. (1991) 148:231-235.
44. JANN MW, LIU H-C, WEIN F-C et al.: Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients. Hum. Psychopharmacol. (1997) 12:489-495.
45. OLESEN OV, POULSEN B: On-line fully automated determination of clozapine and desmethylclozapine in human serum by solid-phase extraction on exchangeable cartridges and liquid chromatography using a methanol buffer mobile phase on unmodified silica. J. Chromatog. (1993) 622:39-46.
46. MANNENS G, MEULDERMANS W, SNOECK E, HEYKANTS J: Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (1994) 114:566-572.
47. BALANT-GORGIA AE, GEX-FABRY M, GENET C, BALANT LP: Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther. Drug Monit. (1999) 21:105-115.
48. MACKAY AVP, HEALEY AF, BAKER J: The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. Br. J. Clin. Pharmacol. (1974) 1:425-430.
49. RIVERA-CALIMLIM L, GIFT T, NASRALLAH HA, WYATT RJ, LASAGNA L: Correlation between plasma concentrations of chlorpromazine and clinical response. Commun. Psychopharmacol. (1978) 2:215-222.
50. TOKUNAGA H, KUDO K, IMAMURA T, JITSUFUCHI N, OHTSUKA Y, IKEDA N: Plasma concentrations of antipsychotic drugs in psychiatric inpatients. Nippon Hoigaku Zasshi (1997) 51:417-422.
51. WODE-HELGODT B, ALFREDSSON G: Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed doses. Psychopharmacology (1981) 73:55-62.
52. ALFREDSON G, SEDVALL G: Protein binding of chlorpromazine in cerebrospinal fluid and serum. Int. Pharmacopscychiatry (1980) 15:261-269.
53. JøRGENSEN A, ANDERSEN J, BJøRNDAL N, DENCKER SJ, LUNDIN L, MALM U: Serum concentrations of cis(Z)flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate. Psychopharmacology (1982) 77:58-85.
54. JøRGENSEN A, GOTTFRIES CG: Pharmacokinetic studies on flupenthixol and flupenthixol decanoate in man using tritium labeled compounds. Psychopharmacologia (1972) 27:1-10.
55. HARRIS PQ, BROWN SJ, FRIEDMAN MJ, BACOPOULOS NG: Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics. Biol. Psychiat. (1984) 19:849-860.
56. VERBEECK RK, CARDINAL J-A, HILL AG, MIDHA KK: Binding of phenothiazine neuroleptics to plasma proteins. Biochem. Pharmacol. (1983) 32:2565-2570.
57. 2 atypical antipsychotics. Am. J. Psychiat. (2005) 162:1984-1985.
58. 2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int. J. Neuropsychopharmacol. (2004) 7:19-26.
59. RAEDLER TJ, KNABLE MB, JONES DW et al.: In vivo olanzapine occupancy of muscarinic acetylcholine rceptors in patients with schizophrenia. Neuropsychopharmacology (2000) 23:56-68.
60. 2 receptor (not high affinity at multiple receptors) is the key to 'atypical' antipsychotics. Schizophrenia Ret. (2001) 49(1-2 Suppl.):92.
61. ÖGREN, SO, FLORVALL U, HALL H, MAGNUSSON O, ÄNGEBY-MÖLLER K: Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiat. Scand. (1990) 82(Suppl. 358):21-26.
62. MELTZER HY, NASH JF: Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. (1991) 43:587-604.
63. 2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am. J. Psychiatry (1998) 155:505-508.
64. KAPUR S LANGLOIS X, VINKEN P. MEGENS AA, DE COSTER R, ANDEWS JS: The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. (2002) 302:1129-1134.
65. 2A receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol. Biochem. Behav. (2001) 68:363-370.
66. 4. Neuropsychopharmacology (1997) 16:93-110.
67. SEEMAN P, KAPUR S: Olanzapine binding to dopamine receptors in vitro and in vivo. In: Olanzapine (Zyprexa) - A Novel Antipsychotic. Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds), Eli Lilly & Co., Lippincott Williams & Wilkins, Philadelphia, USA (2000):3-24.
68. 2 receptor occupancy studies and clinical response. Br. J. Psychiat. (1996) 168:40-44.
69. KALKMAN HO, NEUMANN V, NOZZULAK J, TRICKLEBANK MD: Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur. J. Pharmacol. (1998) 343:201-207.
70. MELTZER HY, LEE MA, RANJAN R, MASON EA, COLA PA: Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine. Psychopharmacology (Berl) (1996) 124:176-187.
71. INVERNIZZI RW, CERVO L, SAMANI R: 8-Hydroxy-2-(Di-N-propylamino)tetralin, a selective serotonin-1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology (1988) 27:515-518.
72. WADENBERG M-L: Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH23390 in the rat. J. Neural Transm. (1992) 89:4-9.
73. KLEVEN MS, BARRET-GREVOZ C, SLOT LB. NEWMAN-TANCREDI A: Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology (2005) 49:135-143.
74. 2 dopamine receptor occupancy: A crossover comparison of risperidone with clozapine therapy in schizophrenic patients. Arch. Gen. Psychiat. (1997) 54:972-973.
75. 2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiat. (2005) 62:371-378
76. GLATT SJ, JONSSON EG: The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: evidence from fixed- and random-effects meta-analyses. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2006) 141:149-154.
77. 2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neuroimage (2006) 29:662-666.
78. 3 receptor agonist in schizophrenia. Eur. Neuropsychopharmacol. (2003) 13:(Suppl. 4):S167-S168.
79. 3 receptor agonist. Nature (1999) 400:371-375.
80. 3 receptor and drug addiction. Neurotox. Res. (2001) 3:433-441.
81. 3 receptor antagonists as therapeutic agents. Drug Discov. Today (2005) 10:917-925.
82. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Rev. (2005) 49:77-105.
83. LIEBERMAN JA, KANE JM, ALVIR J: Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (1987) 91:415-433.
84. CURRAN C, BYRAPPA C, McBRIDE A: Stimulant psychosis: systematic review. Br. J. Psychiat. (2004) 185:196-204.
85. BAUMEISTER AA, FRANCIS JL: Historical development of the dopamine hypothesis of schizophrenia. J. History Neurosci. (2002) 11:265-277.
86. High states, implying many paths to psychosis. Proc. Nat. Acad. Sci. USA (2005) 102:3513-3518.
87. RICHELSON E, SOUDER T: Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci. (2000) 68:29-39.
88. 1 receptor affinity than olanzapine. J. Pharmacol. Exper. Therap. (2005) 315:1265-1277.
89. ROTH BL, CRAIGO SC, CHOUDHARY MS et al.: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exper. Therap. (1994) 268:1403-1410.
90. 7 serotonin receptors: inverse agonist activity of antipsychotic drugs. Psychopharmacology (2005) 179:461-469.
91. 2 high affinity state with positron emission tomography (PET). J. Med. Chem. (2005) 48:4153-4160.
92. 11C]-(+)-PHNO. Biol. Psychiat. (2006) 59:389-394.